Expression of P-glycoprotein and metallothionein in gastrointestinal stromal tumor and leiomyosarcomas. Clinical implications

Pathology and Oncology Research

Volumn 13, Issue 3, 2007, Pages 203-208

  Pérez Gutiérrez, Sofia ^a   González Cámpora, Ricardo ^b   Amérigo Navarro, Joaquín ^c   Beato Moreno, Antonio ^d   Sánchez León, María ^c   Pareja Megía, María Jesús ^b   Virizuela Echaburu, Juan Antonio ^b   López Beltrán, Antonio ^e  

^a Juan Ramon Jimenez Hospital   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^c HOSPITAL TORRECÁRDENAS   (Spain)

^d UNIVERSITY OF SEVILLE   (Spain)

^e HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Gastrointestinal stromal tumors; GIST; Leiomyosarcomas; Metallothionein; P glycoprotein

Indexed keywords

GLYCOPROTEIN P; METALLOTHIONEIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION;

EID: 36849084075     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02893500     Document Type: Article

References (21)

1. Berman J, O'Leary TJ: Gastrointestinal stromal tumor workshop. Hum Pathol 32:578-582, 2001.
2. Dziegiel P, Salwa-Zurawska W, Zurawski J, Wojnar A, Zabel M: Prognostic significance of augmented metallothionein (MT) expression correlated with Ki-67 antigen expression in selected soft tissue sarcomas. Histol Histopathol 2: 83-89, 2005.
3. Edmonson JH, Marks RS, Buckner JC, Mahoney MR: Contrast of response to dacarbazine, mitomycin, doxorubicin and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest 20:605-612, 2002.
4. Endresen L, Bakka A, Rugstad HE: Increased resistance to chlorambucil in cultured cells with a high concentration of cytoplasmic metallothionein. 43: 2918-2926, 1983.
5. Fletcher CMD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW: Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33: 459-465, 2002.
6. Gaumann A, Tews DS, Mentzel T, Petrow PK, Mayer E, Otto M, Kirkpatrick CJ, Kriegsmann J: Expression of drug resistance related proteins in sarcomas of the pulmonary artery and poorly differentiated leiomyosarcomas of other origin. Virchows Arch 442: 529-537, 2003.
7. Hegedus T, Orfi L, Seprodi A, Varadi A, Sarkadi B, Keri G: Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta 1587: 318-325, 2002.
8. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumors. J Clin Oncol 21:4342-4349, 2003.
9. Hirota S, Isozaki K: Pathology of gastrointestinal stromal tumors. Pathol Int 56:1-9, 2006.
10. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577-580, 1998.
11. Joensuu H, Roberts PJ, Sarlomo-Rikala M Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD: Effect of the tyrosine kinase inhibitor STI571 in a patient with metastatic gastrointestinal stromal tumors. N Engl J Med 344:1052-1056, 2001.
12. Kagi JHR: Overview of metallothionein. Methods Enzymol 205: 613-626, 1991.
13. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM: Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152:1259-1269, 1998.
14. Lehnert T: Gastrointestinal sarcoma (GIST) - a review of surgical management. Ann Chir Gynecol 87: 297-305, 1998.
15. Merino V, Relevance of multidrug resistance proteins on the clinical efficacy of cancer therapy. 1: 203-212, 2004.
16. Nilsson B, Bumming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B, Sablinska K, Kindblom LG: Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - a population-based study in western Sweden. Cancer 103: 821-829, 2005.
17. Ning ZQ, Li J, Arceci RJ: Activating mutation of c-kit at codon 816 confers drug resistance in human leukemia cells. Leuk Lymphoma. 41: 513-522, 2001.
18. Plaat BEC, Hollema H, Willemina MM: Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 18: 3211-3220, 2000.
19. Theou N, Gil S, Devocelle A Julie C,Lavergne-Slove A, Beauchet A, Callard P, Farinotti R, Le Cesne A, Lemoine A, Faivre-Bonhomme L, Emile JF: Multidrug resistance proteins in gastrointestinal stromal tumors: site-dependent expression and initial response to imatinib. Clin Cancer Res 11: 7593-7598, 2005.
20. th ed., Mosby, St. Louis, 2001.
21. Zwelling A, Slovak ML, Doroshow JH, Hinds M, Chan D, Parker E, Mayes J, Sie KL, Meltzer PS, Trent JM: HT1080/DR4: A P-Glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug sensitive topoisomerase II. J Natl Cancer Inst 82: 1553-1561, 1990.